LCTX LINEAGE CELL THERAPEUTICS IN revenue, earnings and financials
For the quarter ended June 30, 2026, LINEAGE CELL THERAPEUTICS IN reported revenue of $1.07M (down 61.3% from a year earlier), net income of $1.48M and diluted EPS of −$0.03; over the last four quarters revenue was $13.1M and net income −$32.3M; for the fiscal year ended December 2025 revenue was $14.6M, up 53.2% on the year before.
LCTX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $14.6M, gross profit n/a, operating income −$36.6M, net income −$63.5M (margin -436.5%), EPS −$0.28
- Fiscal year ended Dec 2024: revenue $9.50M, gross profit n/a, operating income −$21.5M, net income −$18.6M (margin -195.9%), EPS −$0.09
- Fiscal year ended Dec 2023: revenue $8.95M, gross profit $8.27M, operating income −$24.7M, net income −$21.5M (margin -240.2%), EPS −$0.12
- Fiscal year ended Dec 2022: revenue $14.7M, gross profit $14.0M, operating income −$22.5M, net income −$26.3M (margin -178.7%), EPS −$0.15
- Fiscal year ended Dec 2021: revenue $4.34M, gross profit $2.92M, operating income −$49.2M, net income −$43.0M (margin -991.0%), EPS −$0.26
LCTX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $1.07M (down 61.3% year over year), net income $1.48M, EPS −$0.03
- Quarter ended Mar 31, 2026: revenue $1.73M (up 14.8% year over year), net income −$4.81M, EPS −$0.03
- Quarter ended Dec 31, 2025 (from the annual report): revenue $6.61M (up 130.4% year over year), net income $851K, EPS $0.00
- Quarter ended Sep 30, 2025: revenue $3.68M (down 2.6% year over year), net income −$29.8M, EPS −$0.13
- Quarter ended Jun 30, 2025: revenue $2.77M (up 96.4% year over year), net income −$30.5M, EPS −$0.13
- Quarter ended Mar 31, 2025: revenue $1.50M (up 4.0% year over year), net income −$4.14M, EPS −$0.02
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.87M (up 37.4% year over year), net income −$3.27M, EPS $0.00
- Quarter ended Sep 30, 2024: revenue $3.78M (up 203.3% year over year), net income −$3.03M, EPS −$0.02
- Quarter ended Jun 30, 2024: revenue $1.41M (down 56.3% year over year), net income −$5.76M, EPS −$0.03
- Quarter ended Mar 31, 2024: revenue $1.44M (down 39.5% year over year), net income −$6.54M, EPS −$0.04
- Quarter ended Dec 31, 2023: revenue $2.09M (up 9.0% year over year), net income −$4.78M, EPS −$0.03
- Quarter ended Sep 30, 2023: revenue $1.25M (down 58.4% year over year), net income −$7.11M, EPS −$0.04
- Quarter ended Jun 30, 2023: revenue $3.23M (down 29.2% year over year), net income −$5.23M, EPS −$0.03
- Quarter ended Mar 31, 2023: revenue $2.39M (down 54.4% year over year), net income −$4.37M, EPS −$0.03
- Quarter ended Dec 31, 2022: revenue $1.92M (up 64.0% year over year), net income −$6.35M, EPS −$0.03
- Quarter ended Sep 30, 2022: revenue $3.00M (up 32.1% year over year), net income −$6.07M, EPS −$0.04
- Quarter ended Jun 30, 2022: revenue $4.55M (up 789.3% year over year), net income −$6.76M, EPS −$0.04
- Quarter ended Mar 31, 2022: revenue $5.24M (up 1239.4% year over year), net income −$7.09M, EPS −$0.04
- Quarter ended Dec 31, 2021: revenue $1.17M, net income −$29.0M, EPS −$0.17
- Quarter ended Sep 30, 2021: revenue $2.27M, net income −$7.82M, EPS −$0.05
LCTX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$18.9M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$23.1M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$28.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow $1.06M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$23.6M, share buybacks n/a
LCTX balance sheet
- Jun 30, 2026: cash $37.4M, total assets $106M, total liabilities $46.4M, shareholders' equity $60.9M
- Mar 31, 2026: cash $35.9M, total assets $110M, total liabilities $56.8M, shareholders' equity $53.9M
- Dec 31, 2025: cash $40.8M, total assets $113M, total liabilities $69.2M, shareholders' equity $44.5M
- Sep 30, 2025: cash $40.5M, total assets $89.6M, total liabilities $68.8M, shareholders' equity $22.0M
- Jun 30, 2025: cash $42.3M, total assets $90.8M, total liabilities $43.7M, shareholders' equity $48.4M
- Mar 31, 2025: cash $47.9M, total assets $112M, total liabilities $34.1M, shareholders' equity $79.0M
- Dec 31, 2024: cash $45.8M, total assets $113M, total liabilities $36.2M, shareholders' equity $78.4M
- Sep 30, 2024: cash $27.8M, total assets $96.6M, total liabilities $31.8M, shareholders' equity $66.2M
What is LCTX's revenue?
LINEAGE CELL THERAPEUTICS IN reported $13.1M of revenue over its last four quarters, through June 30, 2026.
Is LCTX profitable?
No. LINEAGE CELL THERAPEUTICS IN lost $32.3M over the last four quarters.
What is LCTX's EPS?
Diluted earnings per share over the last four quarters were −$0.19; −$0.03 in the latest quarter.